4 OVERVIEW

4 Drug Overview

5 Product Profiles

5 Stivarga : Hepatocellular carcinoma (HCC)

14 Stivarga : Colorectal cancer (CRC)

LIST OF FIGURES

10 Figure 1: Datamonitor Healthcare's drug assessment summary of Stivarga for HCC

11 Figure 2: Datamonitor Healthcare's drug assessment summary of Stivarga for HCC

13 Figure 3: Stivarga sales for HCC across the US, Japan, and five major EU markets, by country, 2018-27

20 Figure 4: Stivarga for colorectal cancer - SWOT analysis

21 Figure 5: Datamonitor Healthcare's drug assessment summary of Stivarga for colorectal cancer

22 Figure 6: Datamonitor Healthcare's drug assessment summary of Stivarga for colorectal cancer

24 Figure 7: Stivarga sales for colorectal cancer across the US, Japan, and five major EU markets, by country, 2016-25

LIST OF TABLES

6 Table 1: Stivarga drug profile

7 Table 2: Approval history of Stivarga for HCC in the US, Japan, and five major EU markets

8 Table 3: Trials of Stivarga for HCC

9 Table 4: Stivarga for HCC - SWOT analysis

15 Table 5: Stivarga drug profile

17 Table 6: Stivarga pivotal trial data in colorectal cancer

19 Table 7: Stivarga ongoing trials in colorectal cancer

25 Table 8: Stivarga sales for colorectal cancer across the US, Japan, and five major EU markets, by country ($m), 2016-25
27 Table 9: Patients treated with Stivarga across the US, Japan, and five major EU markets, by country, 2016-25